Their study found that ERα-positive breast cancer patients with less than 80% AR expression had a higher risk of relapse than patients with more than 80% AR expression, and these patients with higher AR expression had lower nuclear grade and lower proliferative properties (e.g., lower Ki-67) measured in their tumors. The gene discussed is ESR1; the disease is breast carcinoma.